Hangzhou Pollen Group Company Limited announced that it will receive CNY 115,000,000 in an equity round of funding on November 27, 2020. The transaction will include participation from existing investor, ShanXi C&Y Pharmaceutical Group Co., Ltd. (SZSE:300254). The transaction has been approved in the 15th meeting of the parent of the company's 4th directorate and the 8th meeting of the 4th supervisory board and does not need its shareholders’ approval.